| IV-37 Ana-Marija Grisic Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study Thursday 15:25-16:50 |
| IV-37 Ana-Marija Grisic Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study Thursday 15:25-16:50 |